// App-Quantinova.ai

413 : Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial

Researchers

Presenter

  • Patrice Chevallier

Principal Investigators

  • Myriam Labopin

  • Gerard Socie

  • Didier Blaise

  • Mauricette Michallet

  • Karin Bilger

  • Philippe Moreau

  • Mohamad Mohty

  • Stephane Vigouroux

  • Sabine Furst

  • Marie Y. Detrait

  • Bruno Lioure

  • Thierry Guillaume

  • Jacques Delaunay

  • Regis Peffault de la Tour

  • Noel Milpied

Medical Centers

  • Hospital Saint Antoine, Paris, France

  • Dermato-Cancerology department, Nantes University Hospital, Nantes, France

  • Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

  • Pediatric Hematology, Nantes University Hospital, Nantes, France

  • University Hospital of Bordeaux, Bordeaux, France

  • Hopital Saint Antoine and Universite Pierre et Marie Curie, Paris, France

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Hematology Department G, Centre Hospitalier Lyon Sud/ Universite de Lyon EST/, Pierre Benite, France

  • CHU Bordeaux, Service dHematologie et de Therapie Cellulaire, Pessac, France

  • Hematology Clinic, CHU Nantes, Nantes, France

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • CHU Hautepierre, Universite Strasbourg, Strasbourg, France

  • CHU Stasbourg, Strasbourg, France

  • HEMATOLOGY, Institut Paoli Calmettes, marseille, France

  • Hematology Dpt, Hopital Saint-Antoine, University UPMC, INSERM, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Thymoglobuline

  • Cyclosporine eent

  • Clofarabine

  • fludarabine tablet

  • Cladribine

  • Busulfan

  • Filgrastim

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved